Shares of Moderna slid 5.17% to $95.81 at 09:51 EST on Tuesday, after two consecutive sessions in a row of gains. The Nasdaq Stock Market is rising 0.22% to $11,880.60, following yesterday’s upward trend, on what up to now seems, a somewhat positive trend trading session today.
According to yesterday’s article on Bloomberg Quint, “Moderna Chief Sells More Shares Ahead of Urgent Vaccine Filing.”
Moderna’s last close was $97.61, below its 52-week high of $103.20.
Moderna’s sales growth is 1216.8% for the ongoing quarter and 2299% for the next. The company’s growth estimates for the present quarter is a negative 67.6% and positive 142.9% for the next.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s stock is valued at $95.81 at 09:51 EST, below its 52-week high of $103.20 and way above its 52-week low of $17.68.
Moderna’s worth is way above its 50-day moving average of $76.35 and way above its 200-day moving average of $69.55.
According to Bloomberg Quint on Fri Nov 20, “EU Could Approve BioNTech, Moderna Vaccines in December.”